Loading...
Market
Regulatory body to impose additional fines on GSK for Zantac by end of 2025?
3
Resolution / Starting Odds
FDA • 25%
FTC • 25%
SEC • 25%
None • 25%
Announcements from regulatory bodies or court filings
Story
GSK Settles 93% of Zantac Cancer Lawsuits for $2.2 Billion
Oct 9, 2024, 06:59 PM
GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle approximately 80,000 U.S. state court lawsuits alleging that its discontinued heartburn medication Zantac, known generically as ranitidine, caused cancer. The settlement covers 93% of the pending product liability cases and involves agreements with ten plaintiff firms, expected to be finalized by the first half of 2025. GSK will recognize a £1.8 billion ($2.3 billion) charge in its third-quarter 2024 results due to the settlement. The U.S. Food and Drug Administration had previously asked manufacturers to remove Zantac from the market over concerns that an ingredient could degrade into a carcinogen. Following the announcement, GSK shares jumped as much as 6.5%.
View original story
Similar markets
Less than $2.5 billion • 25%
$2.5 billion to $3 billion • 25%
$3 billion to $3.5 billion • 25%
More than $3.5 billion • 25%
Less than 90% • 25%
90% to 95% • 25%
95% to 99% • 25%
100% • 25%
Decrease by more than 10% • 25%
Decrease by 5% to 10% • 25%
Decrease by less than 5% • 25%
No significant change • 25%
Stock price increases • 25%
Stock price decreases • 25%
Stock price remains stable • 25%
Insufficient data • 25%
Less than 3 • 25%
3 to 5 • 25%
6 to 10 • 25%
More than 10 • 25%